• 1
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 188899.
  • 2
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 3
    Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 28892.
  • 4
    Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 8629.
  • 5
    Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare side effects which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85: 16982.
  • 6
    Lanas A. Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology (Oxford) 2002; 41(Suppl. 1): 1622; discussion 35–42.
  • 7
    Lanas A, Martin-Mola E, Ponce J, Navarro F, Pique JM, Blanco FJ. Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents. Gastroenterol Hepatol 2003; 26: 485502.
  • 8
    Lanas A. Impacto económico de los efectos secundarios gastrointestinales asociados a antiinflamatorios no esteroideos en el Servicio Nacional de Salud. Med Clin (Barc) 2000; 114(Suppl. 3): 4653.
  • 9
    Lanas A, Hirschowitz BI. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999; 11: 37581.
  • 10
    Lanas A, Arroyo MT. Antisecretory drugs and prophylaxis of secondary gastrointestinal effects associated with the consumption of non steroid anti-inflammatory drugs. Med Clin (Barc) 2000; 114(Suppl. 2): 5762.
  • 11
    Schoenfeld P. An evidence-based approach to the gastrointestinal safety profile of COX-2-selective anti-inflammatories. Gastroenterol Clin North Am 2001; 30: 102744.
  • 12
    Thompson AJ, Yeomans ND. COX-2 inhibition versus gastroprotection with dual COX inhibitors: an evidence-based approach. Curr Pharm Des 2003; 9: 22218.
  • 13
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 2419.
  • 14
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 124755.
  • 15
    Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 192933.
  • 16
    Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 168190.
    Direct Link:
  • 17
    Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 96773.
  • 18
    Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 210410.
  • 19
    Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123: 100612.
  • 20
    Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996; 28: 20410.
  • 21
    Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 8349.
  • 22
    Navarro MA, Raei N, Torres F, et al. Differences in the release of omeprazole in 4 commercial preparations: influence of pH and ionic concentration. Gastroenterol Hepatol 1998; 21: 6370.
  • 23
    Palummo M, Cingolani A, Dall L, Volonte MG. Stability of capsules containing omeprazole in enteric coated pellets. Boll Chim Farm 2000; 139: 1248.
  • 24
    Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs. Arch Intern Med 2002; 161: 16975.
  • 25
    Yeomans H, Hawkey C, Jones R, et al. Esomeprazole provides effective control of NSAID-associated upper GI symptoms in patients continuing to take NSAIDs. Gastroenterology 2003; 124: A-107 (Abstract 797).
  • 26
    Kimmey M, Lanas A. Review article: Appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004; 19(Suppl. 1): 605.
  • 27
    Hunt RH, Bowen B, Mortensen ER, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000; 109: 2016.
  • 28
    Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 62430.
  • 29
    Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002; 72: 5061.
  • 30
    Sturkenboom MC, Burke TA, Tangelder MJD, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003; 18: 113748.
  • 31
    Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003; 42(Suppl. 3): iii2331.